Bioliberty is one of those Scottish deep-tech companies that is easy to under-notice. It’s quiet on social media, doesn’t push much into the tech press, is FDA-listed, ships a physical product manufactured in Fife, and commercialises through American healthcare rather than the NHS. Readers who follow Scottish medtech closely will already have seen the March 2026 Series A headlines. It might still be worth spending a little time on what the company is actually building, and on the small handful of decisions that have taken it from a lockdown flatmate project to the only Scottish name on Medical Futurist’s Top 100 Digital Health and AI Companies of 2026.
The technology, briefly
The flagship product is Lifeglov — a soft-robotic glove designed for patients recovering from stroke and other neurological events that impair upper-limb function. What’s slightly different about it is the mechanism. Where most powered rehab devices are motorised exoskeletons built around rigid joints, Lifeglov is pneumatic: controlled air pressure drives compliant actuators that extend and flex the wearer’s fingers, and the compliance profile is closer to a therapist’s hand than to a machine.
The spec sheet quietly signals a product built for clinical throughput rather than laboratory demonstration. The glove can be donned in about two minutes, even on patients presenting with Modified Ashworth Scale 4 spasticity — a materially difficult category to work with. A single session can deliver up to 210 flexion and extension cycles across a range of therapy modes, from fully passive (the glove does the work) to actively assisted (the patient initiates, the glove supports). And the whole thing has been FDA-listed since December 2024.
Lifeglov sits inside a broader product, Lifehub Clinic, with a clinician-facing analytics layer called Lifemind on top. Bioliberty describes the combined stack as a functional-intelligence platform for post-acute rehabilitation, which is a phrase that reads slightly better if you’ve spent any time inside a US inpatient rehab facility trying to work out what to actually measure.
The founding story, and where the company sits geographically
The company was founded in June 2020 by four University of Edinburgh flatmates and friends — Ross O’Hanlon, Rowan Armstrong, Shea Quinn and Conan Bradley. The origin, per Series A Stories’ write-up in March 2026, is that O’Hanlon watched a relative with MS lose the use of her hands, brought Armstrong, Quinn and Bradley in, and the four of them started building.
The Series A, and a board worth pausing on
The March 2026 Series A came in at £6.2m as the headline round, and forms part of a broader £7.7m raise across the preceding ten months. The Scottish National Investment Bank led with £3m — a materially larger lead cheque than SNIB was writing three years ago, and, as it happens, one more data point in the growing set that suggests the bank is settling into a genuinely lead-investor posture rather than the passive follow-on stance it was often characterised as taking early on.
Returning investors Archangels, Eos Advisory, Old College Capital and Hanna Capital SEZC all rolled over. Conduit Connect joined as a new investor. So far, so orderly. What’s a little less orderly for a Series A of this size is the board that came with it.
The commercialisation choice — and the thing that seems worth observing
The strategic decision that’s probably worth pausing on is the one Bioliberty took on where to commercialise first. The company launched Lifehub Clinic commercially in mid-2025, and as of the Series A disclosures it was in use across a number of leading American rehabilitation facilities. The NHS was, at least for now, set to one side.
The rationale is straightforward enough. US post-acute rehabilitation is a large, private-sector, fee-for-service market where a relatively small number of scaled buyers — Lifepoint being a good example — make purchasing decisions on clinical throughput and patient-outcome metrics on relatively short timescales. Lifehub Clinic is priced and specified for exactly that buyer. NHS procurement, by comparison, tends to ask a stage-appropriate Scottish medtech company to spend 18 to 24 months navigating trust-by-trust adoption before it has the American traction on which a Series B can reasonably be based.
None of that is a criticism of Bioliberty’s choice. It is, on any rational reading, the right one for the stage the company is at. It’s more that readers who look at the Scottish policy conversation about scaling indigenous medtech might find it useful to note the mismatch: the Scottish system routinely calls for Scottish companies to scale in Scotland, but the procurement infrastructure it operates isn’t currently calibrated to the commercialisation timelines those companies actually need to run on. Bioliberty’s decision to build Scottish jobs while taking revenue from American healthcare buyers is a rational company response to that gap, and probably worth noting in the read of the Series A rather than as a separate policy critique.
Recognition and where the company goes next
In addition to the Series A, Bioliberty was named in June to Medical Futurist’s Top 100 Digital Health and AI Companies of 2026 — the only Scottish company on the list. As external signals go, that’s a reasonably useful one.
Medtech commercialisation cycles are long, US healthcare purchasing decisions are exogenous to anything Bioliberty can control, and Series B market conditions in 2027 will be whatever they are. But the shape of the company at the end of H1 2026 is that of one of the small handful of Scottish deep-tech operators genuinely positioned to become a scaled, Scottish-headquartered medtech company with materially international revenue by the end of the decade. That’s a rare shape in the Scottish tech landscape, and probably worth tracking closely.
Silicon will look at fellow Archangels-backed Edinburgh spin-out Biocaptiva later this week.
